E M Grischke
Overview
Explore the profile of E M Grischke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
213
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gluz O, Kuemmel S, Nitz U, Braun M, Ludtke-Heckenkamp K, von Schumann R, et al.
Ann Oncol
. 2023 Apr;
34(6):531-542.
PMID: 37062416
Background: In high-risk hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC), nanoparticle albumin-bound (nab)-paclitaxel showed promising efficacy versus solvent-based (sb)-paclitaxel in neoadjuvant trials; however, optimal patient...
2.
Clover A, De Terlizzi F, Bertino G, Curatolo P, Odili J, Campana L, et al.
Eur J Cancer
. 2020 Aug;
138:30-40.
PMID: 32836172
Background: Electrochemotherapy (ECT) is a treatment for both primary and secondary cutaneous tumours. The international Network for sharing practices on ECT group investigates treatment outcomes after ECT using a common...
3.
Mavratzas A, Baek S, Gerber B, Schmidt M, Moebus V, Foerster F, et al.
Breast
. 2019 Mar;
45:22-28.
PMID: 30822621
Background: This multicenter, double-blind phase II study assessed the antitumor activity and toxicity profile of docetaxel with the antiangiogenic multikinase inhibitor sorafenib or matching placebo as a first-line treatment in...
4.
Wuerstlein R, Kates R, Gluz O, Grischke E, Schem C, Thill M, et al.
Breast Cancer Res Treat
. 2019 Feb;
175(2):389-399.
PMID: 30796651
Purpose: The WSG-PRIMe Study prospectively evaluated the impact of the 70-gene signature MammaPrint® (MP) and the 80-gene molecular subtyping assay BluePrint® on clinical therapy decisions in luminal early breast cancer....
5.
Dinkic C, Eichbaum M, Schmidt M, Grischke E, Gebauer G, Fricke H, et al.
Gynecol Oncol
. 2017 May;
146(2):279-284.
PMID: 28528917
Purpose: The prognosis is poor for patients with recurrent, platinum-resistant epithelial ovarian cancer (EOC). Evidence suggests that antiangiogenic treatment modalities could play a major role in EOC. A combined therapy...
6.
Bachmann C, Schmidt S, Staebler A, Schittenhelm J, Wallwiener D, Grischke E
Med Oncol
. 2014 Feb;
31(3):862.
PMID: 24504842
The development of brain metastases (BM) of primary breast cancer patients leads to limited survival. HER2-positive and triple-negative status are risk factors for the development of BM. Estrogen receptor (ER)/progesterone...
7.
Bachmann C, Grischke E, Staebler A, Schittenhelm J, Wallwiener D
J Cancer Res Clin Oncol
. 2013 Sep;
139(11):1909-16.
PMID: 24037487
Objective: A challenge in the management of breast cancer is development of brain metastases (BM) with limited survival. In primary breast cancer, ER/PR/HER2 are important prognostic markers and are important...
8.
Bachmann C, Grischke E, Fehm T, Staebler A, Schittenhelm J, Wallwiener D
J Cancer Res Clin Oncol
. 2012 Dec;
139(4):551-6.
PMID: 23224376
Purpose: A challenge in management of breast cancer is the development of brain metastases (BM). Because of improvements in systemic therapy with longer survival of patients with advanced cancer, BM...
9.
Bachmann C, Bachmann S, Fehm T, Staebler A, Becker S, Rothmund R, et al.
J Cancer Res Clin Oncol
. 2011 Nov;
138(2):261-7.
PMID: 22105899
Purpose: Prognostic impact of nodal status or lymphadenectomy in advanced ovarian cancer is still unclear. Known best prognostic impact in advanced ovarian cancer has the residual tumor mass. The aim...
10.
Grischke E, Kagan K, Abele H
MMW Fortschr Med
. 2008 Nov;
150(44):40-2, 44.
PMID: 19024491
No abstract available.